Cooper D, Zolopa A, Rockstroh J, et al. Subgroup analyses of 96-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF. Program and abstracts of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30 - July 3, 2013; Kuala Lumpur, Malaysia. Abstract TUPE281.